Trowbridge Stephen A

SEC source: 0001567619-22-001116 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,081

SEC source: 0001567619-21-015946 · doc1.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,357 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On October 16, 2019, the reporting person received a target grant of 8,357 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

F3 · derivative.exercise_date: On October 16, 2019, the reporting person received a target grant of 8,357 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

F3 · derivative.expiration_date: On October 16, 2019, the reporting person received a target grant of 8,357 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

SEC source: 0001567619-21-015946 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,308

F2 · shares: The exempt disposition of 1,231 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-21-015946 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,539

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 3,231 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-21-016021 · doc1.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,437 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: On July 18, 2018, the reporting person received a target grant of 9,437 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 10,946 shares of Common Stock were issued to the reporting person under this grant.

F4 · derivative.exercise_date: On July 18, 2018, the reporting person received a target grant of 9,437 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 10,946 shares of Common Stock were issued to the reporting person under this grant.

F4 · derivative.expiration_date: On July 18, 2018, the reporting person received a target grant of 9,437 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 10,946 shares of Common Stock were issued to the reporting person under this grant.

SEC source: 0001567619-21-016021 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,081

F1 · security: On August 17, 2021, the reporting person filed a Form 4 to report the vesting and settlement of performance share units and the sale of certain underlying shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance share units and the number of shares of Common Stock of the Company issued and sold.

F3 · shares: The exempt disposition of 4,173 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-016021 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,254

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: On August 17, 2021, the reporting person filed a Form 4 to report the vesting and settlement of performance share units and the sale of certain underlying shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance share units and the number of shares of Common Stock of the Company issued and sold.

F2 · shares: This acquisition of 10,946 shares of Common Stock of the Company represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-014062 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,308

F1 · shares: The exempt disposition of 353 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001567619-21-013929 · doc1.xml · derivative · entry 6

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,128

Underlying: Common Stock · 20,128 shares

Expires 2031-07-21

F6 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-013929 · doc1.xml · derivative · entry 5

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,817

Underlying: Common Stock · 14,817 shares

Expires not disclosed

F5 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-21-013929 · doc1.xml · nonDerivative · entry 4

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,661

F4 · shares: The acquisition of 7,408 shares of Common Stock of the Company represents 7,408 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 21, 2022, such that 25% of the restricted stock units will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-022707 · doc1.xml · derivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,128

Underlying: Common Stock · 20,128 shares

Expires 2031-07-21

F1 · security: On July 23, 2021, the reporting person filed a Form 4 to report, among other items, the granting of stock options of AngioDynamics, Inc., which contained an administrative error as to the exercise price of such options.

F2 · derivative.exercise_date: The exempt disposition of 354 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001567619-21-013929 · doc1.xml · nonDerivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,253

F3 · shares: The exempt disposition of 400 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-013929 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,653

F2 · shares: The exempt disposition of 354 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001567619-21-013929 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,007

F1 · shares: The exempt disposition of 1,284 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

SEC source: 0001567619-21-008240 · doc1.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,625 shares

Expires 2021-07-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Options for one-fourth of the shares became exercisable on 7/25/2015, 7/25/2016, 7/25/2017 and 7/25/2018, respectively.

SEC source: 0001567619-21-008240 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,291

F1 · shares: The disposition of 10,080 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. reflects a net exercise of options expiring on July 25, 2021, in which shares of Common Stock were disposed to satisfy the payment of the exercise price and tax withholding obligations.

SEC source: 0001567619-21-008240 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,371

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-002187 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,746

F1 · shares: The exempt disposition of 527 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on February 3, 2020.

SEC source: 0001567619-20-014905 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,273

SEC source: 0001567619-20-013828 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,260

F2 · shares: The exempt disposition of 292 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016.

SEC source: 0001567619-20-013828 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,552

F1 · shares: The exempt disposition of 314 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001567619-20-013548 · doc1.xml · nonDerivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,866

F3 · shares: The exempt disposition of 152 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-20-013548 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,018

F2 · shares: The exempt disposition of 248 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-20-013548 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,266

F1 · shares: The exempt disposition of 354 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001567619-20-013440 · doc1.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,510

Underlying: Common Stock · 44,510 shares

Expires 2030-07-14

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 14, 2021, such that 25% of the options will vest on each of July 14, 2021, 2022, 2023 and 2024.

SEC source: 0001567619-20-013440 · doc1.xml · derivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,242

Underlying: Common Stock · 30,242 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-20-013440 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,620

F1 · shares: This acquisition of 15,121 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 15,121 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 14, 2021, such that 25% of the restricted stock units will vest on each of July 14, 2021, 2022, 2023 and 2024.

SEC source: 0001567619-20-002340 · doc1.xml · derivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP, General Counsel and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,204

Underlying: Common Stock · 18,204 shares

Expires 2030-02-03

F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on February 3, 2021, such that 25% of the options will vest on each of February 3, 2021, 2022, 2023 and 2024.

SEC source: 0001567619-20-002340 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP, General Counsel and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,499

F1 · shares: This acquisition of 5,376 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 5,376 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on February 3, 2021, such that 25% of the restricted stock units will vest on each of February 3, 2021, 2022, 2023 and 2024.

SEC source: 0001567619-19-019778 · doc1.xml · derivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,357

Underlying: Common Stock · 8,357 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-19-015718 · doc1.xml · nonDerivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,723

F3 · shares: The exempt disposition of 285 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016.

SEC source: 0001567619-19-015718 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,008

F2 · shares: The exempt disposition of 306 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001567619-19-015205 · doc1.xml · nonDerivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,669

F3 · shares: The exempt disposition of 355 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 22, 2015.

SEC source: 0001567619-19-015718 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,314

F1 · shares: The exempt disposition of 355 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 22, 2015.

SEC source: 0001567619-19-015205 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,024

F2 · shares: The exempt disposition of 148 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-19-015205 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,172

F1 · shares: The exempt disposition of 241 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-19-015044 · doc1.xml · derivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,975

Underlying: Common Stock · 13,975 shares

Expires 2029-07-17

F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 17, 2020, such that 25% of the options will vest on each of July 17, 2020, 2021, 2022 and 2023.

SEC source: 0001567619-19-015044 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,413

F1 · shares: This acquisition of 4,178 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 4,178 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal installments beginning on July 17, 2020, such that 25% of the restricted stock units will vest on each of July 17, 2020, 2021, 2022 and 2023.

SEC source: 0001567619-19-017322 · doc1.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,894 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 27, 2016, the reporting person received a target grant of 6,894 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 3,585 shares of Common Stock were issued to the reporting person under this grant.

F3 · derivative.exercise_date: On July 27, 2016, the reporting person received a target grant of 6,894 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 3,585 shares of Common Stock were issued to the reporting person under this grant.

F3 · derivative.expiration_date: On July 27, 2016, the reporting person received a target grant of 6,894 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 3,585 shares of Common Stock were issued to the reporting person under this grant.

SEC source: 0001567619-19-017322 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,123

F2 · shares: The exempt disposition of 1,185 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 27, 2016.

SEC source: 0001567619-19-017322 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,308

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 3,585 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 27, 2016.

SEC source: 0001567619-19-009204 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,235

F1 · shares: The exempt disposition of 1,319 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on April 24, 2015.

SEC source: 0001140361-18-034277 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,554

F1 · shares: The exempt disposition of 285 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016.

SEC source: 0001140361-18-033950 · doc1.xml · nonDerivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,839

F3 · shares: The exempt disposition of 306 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001140361-18-033950 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,145

F2 · shares: The exempt disposition of 391 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 25, 2014.

SEC source: 0001140361-18-033950 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,536

F1 · shares: The exempt disposition of 355 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 22, 2015.

SEC source: 0001140361-18-033097 · doc1.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,437

Underlying: Common Stock · 9,437 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-18-033097 · doc1.xml · derivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,032

Underlying: Common Stock · 15,032 shares

Expires 2028-07-18

F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 18, 2019, such that 25% of the options will vest on each of July 18, 2019, 2020, 2021 and 2022.

SEC source: 0001140361-18-033097 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,891

F1 · shares: This acquisition of 4,719 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 4,719 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 18, 2019, such that 25% of the restricted stock units will vest on each of July 18, 2019, 2020, 2021 and 2022.